Kura Oncology, Inc. (NASDAQ:KURA) Receives $26.38 Average Target Price from Analysts

Kura Oncology, Inc. (NASDAQ:KURA) has been assigned a consensus rating of “Moderate Buy” from the thirteen research firms that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation and ten have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $26.3750.

A number of brokerages have recently commented on KURA. Zacks Research raised Kura Oncology from a “strong sell” rating to a “hold” rating in a research note on Thursday, February 26th. Wall Street Zen lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a report on Monday, March 2nd. Wedbush cut their target price on shares of Kura Oncology from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Friday, March 6th. UBS Group reissued a “buy” rating and set a $15.00 target price (down from $16.00) on shares of Kura Oncology in a report on Friday, March 13th. Finally, HC Wainwright restated a “buy” rating and issued a $40.00 price target on shares of Kura Oncology in a research report on Tuesday, January 13th.

Insider Buying and Selling at Kura Oncology

In other Kura Oncology news, insider Teresa Brophy Bair sold 11,208 shares of Kura Oncology stock in a transaction dated Tuesday, January 27th. The stock was sold at an average price of $8.46, for a total transaction of $94,819.68. Following the transaction, the insider directly owned 226,931 shares of the company’s stock, valued at approximately $1,919,836.26. The trade was a 4.71% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Mollie Leoni sold 8,180 shares of the company’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $8.46, for a total value of $69,202.80. Following the completion of the sale, the insider owned 267,274 shares in the company, valued at $2,261,138.04. This trade represents a 2.97% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 36,068 shares of company stock worth $305,135. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Kura Oncology

Hedge funds and other institutional investors have recently made changes to their positions in the stock. IFP Advisors Inc increased its position in Kura Oncology by 115.3% during the 4th quarter. IFP Advisors Inc now owns 2,398 shares of the company’s stock valued at $25,000 after purchasing an additional 1,284 shares during the period. EverSource Wealth Advisors LLC lifted its position in shares of Kura Oncology by 392.8% in the 3rd quarter. EverSource Wealth Advisors LLC now owns 3,854 shares of the company’s stock worth $34,000 after purchasing an additional 3,072 shares during the period. Allworth Financial LP boosted its stake in shares of Kura Oncology by 59.9% in the 4th quarter. Allworth Financial LP now owns 4,146 shares of the company’s stock valued at $43,000 after purchasing an additional 1,553 shares during the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of Kura Oncology by 127.2% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,732 shares of the company’s stock valued at $60,000 after purchasing an additional 3,769 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its position in shares of Kura Oncology by 471.3% during the second quarter. Tower Research Capital LLC TRC now owns 12,071 shares of the company’s stock worth $70,000 after buying an additional 9,958 shares during the period.

Kura Oncology Stock Performance

NASDAQ KURA opened at $9.47 on Friday. The firm’s fifty day moving average price is $8.62 and its two-hundred day moving average price is $9.52. The stock has a market cap of $840.56 million, a PE ratio of -2.98 and a beta of 0.25. The company has a debt-to-equity ratio of 0.06, a quick ratio of 6.05 and a current ratio of 6.06. Kura Oncology has a fifty-two week low of $5.45 and a fifty-two week high of $12.49.

Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.20). Kura Oncology had a negative net margin of 412.95% and a negative return on equity of 102.59%. The firm had revenue of $17.34 million during the quarter, compared to the consensus estimate of $34.71 million. On average, equities analysts expect that Kura Oncology will post -3.36 EPS for the current fiscal year.

About Kura Oncology

Kura Oncology, Inc (NASDAQ: KURA) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted oncology therapies. Headquartered in La Jolla, California, the company leverages expertise in molecular biology and precision medicine to identify key drivers of cancer growth and design small-molecule inhibitors that block those pathways. Kura’s research platform integrates genomic insights with medicinal chemistry to advance candidates against well-validated targets in solid tumors and hematologic malignancies.

The company’s lead clinical candidate, tipifarnib, is a farnesyltransferase inhibitor being evaluated for the treatment of HRAS-mutant head and neck squamous cell carcinoma and various non-small cell lung cancers.